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ABSTRACT
Objective: To determine HIV high risk groups among adults visiting Kenyatta National 
Hospital Voluntary Counselling and Testing Centre by use of Serologic Testing 
Algorithm for Recent HIV Seroconversion (STARHS).
Design: A cross-sectional study of adults.
Setting: Kenyatta National Hospital Voluntary and Counselling Centre.
Results: Of the 6,415 adults screened for antibodies to HIV at Kenyatta National Hospital 
VCT Centre between July 2002 and February 2003, 728 tested positive in the two HIV 
screening tests used at the center, indicating a prevalence of 11%. Of these seropositive 
cases, 355 consented to participate in the study. Using STARHS, 34 (9.6%) of the plasma 
samples were classified as being from individuals with recent infection (within 170 
days), giving an annual estimated HIV-1 incidence in this population of 1.3 infections 
per 100 person-years with a 95% CI of 0.872–1.728%. Young adults had a higher rate 
of new infection than older adults. Young females were infected much earlier in life, 
with a peak age of new infections of 26 years, versus. 31 years for young males.
Conclusion: This study confirms our hypothesis that STARHS or Detuned assay can 
be used to determine HIV incidence in this population. The HIV high risk groups as 
identified by this study are young women between ages 16 to 26 years old and men 
between ages 45 to 55 years of age.
INTRODUCTION
Information on the incidence of human 
immunodeficiency virus (HIV), the causative agent 
of acquired immunodeficiency syndrome (AIDS), is 
limited in many parts of the world, and especially 
sub-Saharan Africa, the region considered to have 
the highest rate of new infections. Accurate incidence 
data are critical to public health surveillance, as they 
allow for more accurate assessment of HIV high-risk 
groups, and thus better targeting of HIV prevention 
programmes. Incidence data also permit more 
accurate estimation of sample sizes for large-scale 
AIDS vaccines trials.
 Patterns of HIV-1 transmission in populations 
can be better followed and measured with incidence 
data. Indeed, several studies (1,2) indicate that stable 
HIV-1 prevalence can sometimes mask substantial 
incidence in population sub-groups with a continuous 
turnover of members, such as injecting drug users 
(IDU) and childbearing women (CBW), among 
others. 
 However, prevalence data are often easier to 
collect than incidence data (1). Heyward et al. (3) have 
shown that HIV-1 prevalence statistics for sub-Saharan 
Africa are increasingly available through longitudinal 
and cross-section studies, whereas empirical 
estimates of HIV-1 incidence remain rare. This may 
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be attributed in part to the lack of rapid methods 
for obtaining incidence statistics. Historically, three 
methods, namely longitudinal cohort studies (4), 
clinical diagnosis for acute retroviral syndrome (5), 
and HIV-1 p24 antigen or RNA-PCR (6), have been 
used to measure incident HIV-1 infection.
 The need to find a diagnostic tool that could 
be used to determine incidence of HIV infection led 
the US Centers for Disease Control and Prevention 
(CDC) to develop an HIV enzyme immunoassay 
(EIA) testing strategy, the so-called Serologic Testing 
Algorithm for Recent HIV Seroconversion (STARHS), 
also known as the ‘detuned test’ (7). STARHS permits 
the determination of the number of very recently 
infected persons (incidence) from among those with 
serologic evidence of HIV-1 infection. The procedure 
uses a sensitive followed by a less sensitive EIA. It 
takes advantage of the progressive development of 
HIV-1 antibody response during the initial phase of 
infection, whereby recently infected individuals are 
seropositive using the sensitive EIA, but non-reactive 
using a less sensitive EIA. Those with long-standing 
HIV-1 infection test positive with both tests (7). STARHS 
can be used to identify persons who seroconverted on 
average within the past 170 days (8).
 The main benefit of STARHS is that for the 
first time, incident HIV-1 infection can be estimated 
through a single cross-section survey, saving on both 
cost and time. We used the STARHS to estimate HIV-1 
incidence in subjects visiting the Kenyatta National 
Hospital Voluntary Counselling and Testing (VCT) 
Centre, and thereby determined HIV-1 high-risk 
groups in this population.
MATERIALS AND METHODS
Study population: Study participants were recruited at 
the Kenyatta National Hospital VCT after obtaining 
ethical clearance from The Kenyatta National 
Hospital Ethics and Research Board. The subjects 
were enrolled in the study after obtaining a signed 
informed consent. Blood samples were taken from 
each subject and screened for antibodies to HIV using 
two rapid tests, namely Abbott Determine HIV-1/2 
(Abbott Diagnostic Division, The Netherlands) and 
Trinity Biotech Uni-Gold (Trinity Biotech plc) and 
were enrolled in the study if their test results indicated 
that they were reactive using both tests. Those with 
any acquired immunodeficiency syndrome (AIDS)-
defining conditions or are suffering from tuberculosis 
(TB) or on TB treatment were excluded from the 
study.
HIV-1/2 screening tests: Venous blood from 355 
subjects was drawn and two aliquots of 0.5ml of 
plasma were frozen.  One aliquot was used for HIV-
1/2 confirmation test and the detune screen assay 
(sensitive), and the other was used for the detune 
test (less sensitive).
Assay controls: Seroconversion samples. To test 
the reliability of the detune assay in a population 
where HIV-1 clade B virus is not known to be 
common, we included samples obtained from 
a cohort of commercial sex workers. Fourteen 
seroconversion samples and 26 samples from those 
with longstanding infection. For the seroconversion 
samples, seroconversion was estimated to have 
occurred midway between the last seronegative 
test and the first seropositive test dates on ELISA, 
as determined from study records. Long-standing 
infection samples were taken from individuals who 
had been infected for at least one year. 
CDC controls: The Centers for Disease Control and 
Prevention (CDC) provided a calibrator and a low 
positive and high positive as controls.
Sensitive assay: Vironostika Uni-Form II (Organon 
Teknika).  This is a fourth-generation EIA and was 
used in this study as a confirmatory test and the 
sensitive assay. The EIA was performed according to 
the manufacturer’s instructions as follows: plasma 
samples were diluted by the addition of 100μl of 
specimen diluent into the micro wells, followed by 
addition of 50μl of specimens or controls into their 
respective wells. The samples were incubated at 37°C 
for one hour.  Unbound antibodies were washed 
followed by addition of 100μl TMB substrate into 
each well. Adding 100μl 1M sulphuric acid to all wells 
stopped the reactions and the results were read at a 
single wavelength of 450nm. Plasma reactive with 
this assay were confirmed as HIV-1/2 seropositive 
and were then processed for the detune assay.
Less-sensitive or detuned assay: Low-sensitivity 
screening assay (Vironostika, OTV-LS EIA) was used 
to determine whether the subjects had recent or 
longstanding HIV infections. All samples confirmed 
by ELISA to have antibodies to HIV were subjected 
to a single run at a DILSIM dilution of 1:20,000. This 
helped exclude samples with long-standing infection 
from those with recent infection. Samples were tested 
in the OTV EIA protocol as described by CDC (8), with 
its subsequent modifications to include a calibrator 
and a low positive control. Briefly, 200μl of the 1:20,000 
dilutions of controls and sample sera were transferred 
to the corresponding wells of the Vironostika HIV-1 
antigen coated plate. The samples and controls were 
then incubated at 37°C for 30 minutes. This was 
followed with a wash step to remove any unbound 
antibodies: 300μl of the wash solution was added to 
each well four times, either manually or by automated 
washer. To each well, 150μl of prepared conjugate was 
added then immediately the plate was incubated at 
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the same conditions as before. Unbound conjugate 
was washed either manually or using an automated 
washer as described above. To each well, 150μl of 
substrate was then added, followed by incubation 
of the plates for 10 to 13 minutes in the dark at room 
temperature. Lastly, 150μl of stop solution was added 
to each well to stop the reaction and immediately 
the plate was read first by blanking the micro-ELISA 
reader on air (without strip holder and strips) and then 
reading the absorbance of the solution in each well 
at 450nm. By using a cut-off of 2.00 for standardized 
optical density (SOD), specimens with SODs > 2.00 
were considered to be from individuals with long-
standing HIV infection and were excluded from 
further detuning. Specimens with SOD < 2.00 were 
subjected to the detuned assay procedure.
‘Detuned’ assay procedure: In this assay sample sera 
and controls were tested in triplicate at 1:20,000 
dilutions. Serum samples from patients and CDC 
controls (calibrator, LPC and HPC) were diluted to 
1:20, 1:400 and 1:20,000 before being tested. 200μl of 
1:20,000 dilution and control samples were transferred 
into the corresponding Vironostika HIV-1 antigen 
coated plate. The rest of the assay was performed 
as for the ‘low sensitive screening assay’ described 
above. Specimen results were expressed as SOD 
calculated from the formula (mean specimen OD 
– mean negative control OD)/mean calibrator OD. 
In this assay (LS EIA) an SOD value of <1.00 was 
used to define those patients as LS EIA non-reactive, 
consistent with infection within the last 170 days.
Data analysis: Statistical analysis was done using SPSS 
for windows package (SPSS Inc. Chicago). Incident 
HIV-1 infection was calculated using the statistical 
module in Microsoft Excel (Microsoft Corp. Seattle, 
WA). Annual estimated HIV incidence was calculated 
as described by Janssen et al (7). The mean time to 
seroconversion used in this study was 170 days (8).
RESULTS
Study population: Between July 2002 and February 
2003, a total of 6,415 men and women were screened 
for antibodies to HIV-1 at Kenyatta National 
Hospital VCT. Out of the 728 seropositive subjects, 
355 individuals aged between 16 and 65 years met 
the criteria to participate in our study (Figure 1) 144 
(41%) males with a median age of 35 years, and 211 
(59%) females with a median age of 30 years. An 
overall prevalence of 11% was calculated from the 
728 seropositive out of the 6,415 subjects screened 
in this clinic for the study period. Figure 1 describes 
how the study subjects were selected.
Figure 1
Flow chart on criteria for study subjects selection. A total of 6,415 subjects visited KNH-VCT between 2002 and 
2003. Of these, 728 tested HIV-1 positive and were asked to join the study. Only 357 consented and were enrolled in 
the study. Further confirmation of sera samples for HIV-1 by ELISA revealed that there were two discordant samples 
leaving 355 samples for further detuning
  
Total number of objects who 
visited LKNH VCT
  HIV-1 screening results
  Consent obtained
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Incident HIV-1 infections as described by STARHS: Out 
of 355 plasma samples confirmed HIV-1 positive, 47 
(13.2%) had an SOD of less than 2.00, and of these, 34 
(9.6%) were classified using the detune screen assay 
as being from individuals with recent infection. An 
incidence of 1.3 infections per 100 person-years (PY) 
with a 95% CI of 0.872% to 1.728% is thus obtained, 
indicating a low rate of new HIV-1 infections in this 
population. Trends of recent HIV-1 infection among 
different age groups in this population showed a bias 
towards young adults aged less than 26 years (Figure 
2). Beyond this age, the number of new infections 
declined significantly: Most people over 26 testing 
positive had longstanding infections. There were 
clear differences between males and females in rate 
of new HIV infections (Figure 3). Fifty-nine per cent 
of the new infections occurred in females, with the 
remaining 41% occurring in males. Females acquired 
HIV-1 infection much earlier in life than did males. 
The peak age for recent HIV infection in females was 
26 years while for males it was 31 years. An interesting 
observation in this study was that, although there 
were hardly any new infections in older women (>35 
years) a few new infections were seen in men in their 
early 40s and below 50 years.
 Validation of detuned assay: One of the limitations 
of this study was lack of enough HIV incidence 
samples for validation in this population. However, 
based on the available samples obtained from 
this population, the detuned assay had a positive 
predictive value (PPV) and negative predictive value 
(NPV) of 85.7% and 92.3% respectively. These results 
suggest that this assay may be used for estimating 
HIV-1 incidence at population level. 
Figure 2
Trends of recent HIV-1 infection among different age groups in this population. There was a rapid increase in new 
HIV-1 infections among young adults aged less than 26 years. Beyond the age of 26 years most people appeared to 
have longstanding infection resulting in a decline in the number of new infections
Table 1
Validation of detuned assay using sera from Kenyan subjects. A total of 40 serum samples were used for this study. 
Fourteen were classified as seroconversion since the first HIV positive test results and the last HIV-1 negative 
results were less than 170 days. The remaining 26 samples were classified as longstanding infection as they had been 
infected with HIV for more than 170 days. These samples were used to validate detuned assay. 
  
HIV-1 infection         HIV-1 Infection as determined 
for more than  by Detuned assay.    
170 days  Recent Longstanding Total
Recent  12 2 14
Longstanding 2 24 26
Total  14 26 40
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DISCUSSION
HIV-1 incidence in adults visiting Kenyatta National 
Hospital VCT centre in Nairobi was estimated using 
STARHS, an approach for detecting recent infections. 
At the time of this study, the HIV-1 prevalence in this 
population was within the national (6-9%) prevalence 
(9). The estimated incidence was generally low 
(1.3/100 person years). However, similar incidence 
data have been observed in a population similar 
to those visiting this facility. Rutherford et al. (10) 
reported an estimated HIV incidence of 1.1 per 100 
person years among subjects attending anonymous 
testing sites in San Francisco, USA. In another study, 
a cohort of men in Bujumbura, Burundi had annual 
HIV-1 incidence of between 1.5 and 2.3% (11). While 
detuned assay was developed and validated for use in 
identifying recent infections in subjects with infections 
to HIV-1 clade B viruses, this assay has been used 
to validate BED HIV-1 Capture EIA Assay, another 
assay used for estimating HIV incidence from subjects 
infected with HIV-1 non-clade B virus (12). 
 Our study found that women became HIV-
infected more frequently, and at an earlier age than the 
male counterparts. There are a number of explanations 
for these differences. The first explanation is lack of 
economic empowerment in young women. In many 
developing countries, young women start having 
sexual relationships at an early age, often with men 
who are much older. Many of these relationships are 
transactional or the result of coercion. A study done 
in Uganda, observed that  new HIV infections were 
highest in young women who had sex with wealthy 
mature men in exchange of material gifts (13). The 
second reason for the high HIV incidence in young 
women than men could be due to the biological or 
anatomical differences between the two sexes. Because 
HIV is mainly transmitted via heterosexual route in 
this population, the vaginal track of women are likely 
to harbor the virus for a longer time upon sexual 
intercourse with an infected person than the genitalia 
of men. This long residence time in the vaginal track 
may give the virus enough time to find its target cells 
and cause infection. Additionally, circumcision in men 
may reduce their ability to get infected with HIV upon 
sexual intercourse. A recent study by Auvert et al (14) 
showed that circumcision can reduce HIV transmission 
in men by a bout 60%. While circumcision has such 
high protective role in men, the same intervention is not 
available for women. The rate of new HIV infections 
in young men peaks in their late 20s and early 30s. 
One possible explanation for this finding is that this 
is the age at which young men marry or start sexual 
relations with young women, some of whom had been 
infected with HIV earlier.  Similar trends have been 
seen in other African countries (15).
 The temporal relationship of age of infection 
with HIV-1 and HIV incidence seen in our study is in 
line with previous findings. Gouws et al. (12), using 
a mathematical model and STARHS, showed that 
incidence and prevalence of HIV-1 infection increases 
rapidly in women aged between 15 and 20, peaks 
among women aged 24 years, and declines among 
older women. 
Figure 3
Shows clear differences between males and females in terms of new HIV infections in different age groups. Females 
in this population acquired HIV-1 infection much earlier in life than males. This is shown by the curve for females 
shifting to the left of the graph compared to that of males on the right. The peak age for recent HIV infection in 
females was 26 years while for males it was 31 years. Fifty nine percent of the new infections occurred in females 
with the remaining 41% of them occurring in males. An interesting observation in this study was that, although 
there were hardly any new infections in older women (>35 years) a few new infections were seen in men in early 40s 
and after 50 years. This shows that a few men continue with high risk sexual behaviour into their 50s
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 The concentration of new HIV-1 infections among 
younger women may indicate a more advanced 
epidemic. In early stages of an epidemic incidence 
of HIV-1 infection will be spread broadly over all age 
groups, particularly where similar proportions of 
women of all ages have multiple partners, or spouses 
with causal or concurrent partners. As the epidemic 
progress, fewer women at high risk will survive 
uninfected into older ages, with the result that the 
age-distribution of HIV-1 incidence will become less 
dispersed and increasingly skewed towards younger 
ages (1, 16, 17).
 Our study has demonstrated that in men, the 
peak at which most men are infected occur much later 
(31years) in life than in women. Similar results have 
been obtained from a European study (19), where 
increase in incidence was strongly skewed towards 
older men (>34 years). In Kenya this fits well with age 
at which most men are getting married to probably 
girls who are already infected with HIV.
 The use of the STARHS to detect new infections 
has a number of shortcomings that may affect 
incidence estimation (19, 20) in Kenya. Detuned 
assay has been validated for use in Europe and North 
America where the most prevalent HIV clade is B. 
As such, validation of this assay was done using 
serum from the Kenyan population. However, even 
though the sample size used for validation was small, 
it picked most of the incidence samples. This study 
demonstrates that age-specific HIV-1 sero-incidence 
is important for the interpretation of cross-section 
sero-incidence surveys. For this reason age should 
be one of the key variables to be collected in HIV 
sentinel studies. However, it must also be remembered 
that trends in HIV incidence among people seeking 
anonymous testing may be influenced by changes 
in test-seeking behaviour as well as changes in 
underlying incidence in the target population (21).
 Finally, a larger sample size of HIV incidence 
sample is needed to validate the use of detuned 
assay in this population. By identifying HIV infected 
persons during acute stage of the infection this can 
help the healthcare giver to educate the infected 
person on ways preventing infection of the other 
sexual partners. Additionally, with the availability 
of free anti-retroviral drugs, such persons can be put 
on treatment depending on the treatment guidelines. 
Treatment of such persons may lead to dramatic 
reduction in viral load and low viral load is associated 
with reduced HIV-1 transmission. Use of detuned 
assay can also help in identifying HIV core transmitter 
groups. Although most HIV-1 core transmitter groups 
such as commercial sex workers are well known, 
this study has identified young women and men in 
their mid forties as other groups that needs targeting 
for intervention. By educating girls especially those 
who have not reached 18 years of age on the risks 
of acquisition of HIV-1, many of the new infections 
among this group could be reduced.  This can help in 
reducing the rate of HIV transmission among acutely 
infected persons to the susceptible persons in the 
population. Additionally, detuned assay will provide 
a tool for determining trends in HIV epidemic as well 
as identifying HIV high risk groups. Since VCTs are 
found in all parts of the country and those visiting 
these centres are people of different demographic 
backgrounds, these centres offer excellent facilities 
for studying the trends of new infections within the 
country.
ACKNOWLEDGEMENTS
To WHO-UNAIDS for providing us with CDC 
controls during a workshop on ‘Application of a 
detuned assay as a tool for estimating HIV-1 incident 
cases for purposes of future HIV-1 vaccine trials’. The 
workshop was held at the Uganda Virus Research 
Institute (UVRI), October–November, 2001.
REFERENCES
1. Batter, V., Matela, B., Nsuami, M. et al. M.E. High 
HIV-1 incidence in young women masked by stable 
overall seroprevalence among childbearing women 
in Kinshasa, Zaire: Estimating incidence from serial 
seroprevalence data. AIDS. 1994; 8: 811–817.
2. Kitayaporn, D., Uneklabh, C., Weniger, B. G. et al. HIV 
incidence determined retrospectively among drug 
users in Bangkok, Thailand. AIDS. 1994; 8: 1443.
3. Heyward, W. L., Osmanov, S., Saba, J. and Esparza, J. 
Preparation for phase III HIV vaccine efficacy trials; 
methods for the determination of HIV incidence. 
AIDS. 1994; 8:1285–1291.
4. McFarland, W., Kellogg, T.A., Dilley, J. and Katz, 
M.H. Estimation of human immunodeficiency virus 
seroprevalence among repeat anonymous testers in 
San Francisco. Am. J. Epidemiol. 1997; 146: 662–664.
5. Schacker, T., Collier, A.C., Hughes, J., et al. Clinical and 
epidemiologic features of primary HIV-1 infection. 
Ann. Intern. Med. 1996; 125: 257–264.
6. Bush, M.P., Lee, L.L., Satten, G.A., et al. Time 
cause of detection of viral and serologic markers 
preceding human immunodeficiency virus type-1 
seroconversion: implications for screening blood and 
tissue donors. Transfusion. 1995; 35: 91–97.
7. Janssen, R.S., Satten, G.A., Stramer, S.L., et al. New 
testing strategy to detect early HIV infection for use 
in incidence estimates and for clinical and prevention 
purposes.  J. Amer. Med. Assoc. 1998; 280: 42–48.
8. Cheluget, B. G., Baltazar, P., Orege., M., et al. Evidence 
for population level declines in adult HIV in Kenya. 
Sex. Transm. Inf. 2006. 82: 21-26.
9. Centers for Disease Control and Prevention. Guide 
to calculating HIV-1 incidence using STARHS 
results from Organon Teknika Corporation (OTV) 
Vironostika less sensitive HIV EIA. Atlanta: Centres 
for Disease Control and Prevention; 2001a.
10. Rutherford, G.W., Schwarcz, S.K. and McFarland, W. 
Surveillance or incident HIV infection: New technology 
and new opportunities. JAIDS 2000; 25: S115–S119.
218 EAST AFRICAN MEDICAL JOURNAL May 2009 
11. Saidel, T., Sokal, D.,  Rice, J.,  et al. Validation of a method 
to estimate age-specific human immunodeficiency 
virus (HIV-1) incidence rates in developing countries 
using population-based seroprevalence data. Am. J. 
Epidemiol. 1996; 144: 214–223.
12. Gouws, E., Brian, G., Williams, Sheppard, H.W., 
et al. High incidence of HIV-1 in South Africa 
using a standardized algorithm for recent HIV 
seroconversion. JAIDS. 2002; 29: 531–535.
13. Opolot, A.J.B. Economic and cultural factors leading 
to risk behaviors among the Giso community. In: 12th 
World AIDS conference, Geneva. (1998). June 28- July 
3: 14206.
14. Auvert, B., Taljaard, D., Lagarde, E.,  et al. Randomized, 
controlled intervention trial of male circumcision for 
reduction of HIV infection risk: The ANRS 1265 trial. 
PLoS Med 2:e298 DOI: 2005.
15. Carael, M., Cleland, J. and Ingham, R. Extra-marital 
sex: implications of survey results for STD/HIV 
transmission. Health Trans. Review. 1994; 4:153–172.
16. UNAIDS/WHO working group on Global HIV/
AIDS. Report on the Global HIV/AIDS Epidemic 
2005. 
17. Konings, E., Blattner, W.A., Levin, A., et al Sexual 
behavior survey in rural area of northwest Tanzania. 
AIDS. 1994; 8: 987–993.
18. Nicole, H.T.M., Spaargaren, D.J., Ronald, B. G., et al. 
HIV incidence on the increase among homosexual 
men attending an Amstardam sexually transmitted 
disease clinic: using a novel approach for detecting 
recent infections. AIDS. 2002; 16: F19–F24. 
19. CDC. HIV incidence among young men who have 
sex with Men— seven US cities, 1994–2000. MMWR 
2001b; 50: 440–444.
20. Notermans, D.W., de Jong, J.J., Goudsmit, J., et al. 
Potent antiretroviral therapy initiates normalization 
of hypergammaglobulinemia and a decline in HIV 
type 1 specific antibody responses. AIDS Res. Hum. 
Retroviruses. 2001; 20:1003–1008.
21. Schwarcz, S., Kellog, T.A., Kohn, R.P., et al. 
Temporal trends in human immunodeficiency virus 
seroprevalence and sexual behavior at the San 
Francisco municipal sexually transmitted disease 
clinic, 1989–1992. Am. J. Epidemiol. 1995; 142: 314–
322.
